An Open-label, Randomized, 2-treatment, 2-sequence, 2-period, Crossover Study to Evaluate the Pharmacokinetics and Safety Between the Administration of AD-229 and the Administration of AD-2291 for Healthy Adults in Fasting State
Latest Information Update: 02 Mar 2026
At a glance
- Drugs AD 229 (Primary) ; AD 2291 (Primary)
- Indications Gastritis
- Focus Pharmacokinetics
- Sponsors Addpharma
Most Recent Events
- 12 Feb 2026 New trial record